Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

REGENXBIO completed enrollment in its ATMOSPHERE and ASCENT trials that will be evaluating surabgene lomparvovec (sura-vec, ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

Nail clubbing, characterized by rounded, thickened, and downward-curved nails, serves as a subtle yet significant indicator ...

Light responsive nanomotors dissolve blood clots and repair vessel tissue by combining catalytic activity, targeted motion, and gentle heating for coordinated thrombolysis and endothelial regeneration ...

Aeston West is thrilled to launch in the beauty market to provide a clinically grounded and botanically informed product ...

Twenty-eight blood-based protein biomarkers, including substance P and CRP, are elevated during sickle cell vaso-occlusive episodes, but not chronic pain.

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo ...

With no weight-loss drug and a focus on cancer, the FTSE 100 giant needs to perfectly manage its patent cliff-edge ...

Developing cardiac inflammatory organoid models incorporating multiple cell lineages is vital for novel therapies.

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions ...